Loading
A phase 2 trial of Carboplatin, Pemetrexed, Ramucirumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Volrustomig Priming Regimens Exploratory Phase II Platform Study is a phase 2 interventional study registered as NCT06448754 by AstraZeneca, with 194 participants enrolled, started 2024-08-27 and due to reach its primary completion in 2027-07-30. Interventions recorded: Volrustomig, Carboplatin, Pemetrexed, Ramucirumab, Paclitaxel. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Ramucirumab, Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, AstraZeneca, Carboplatin, Small-cell lung cancer.